课题基金 / 基金详情

Viral Oncology Career Development Grant

Viral Oncology Career Development Grant
病毒肿瘤学职业发展补助金
批准号:
6798179
负责人:
William J Harrington
金额:
$13.69万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-09-08 至 2006-08-31

项目摘要

项目成果

William J Harrington的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):我的职业生涯已经达到了这样的阶段: 需要对我感兴趣的领域——病毒肿瘤学的独特奉献。 自从我的 研究员,我一直对与病毒相关的淋巴瘤感兴趣。 我们的医疗中心有很多患有这些疾病的患者。 艾滋病毒 相关淋巴瘤很常见,迈阿密是 HTLV-I 的流行区 因此,成人T细胞白血病很常见。 我们有其中之一 最大的器官移植项目和移植后的案例很多 淋巴组织增生性疾病。 我的重点是实验 治疗方法,特别是某些病毒性淋巴瘤如何在 对抗病毒药物的反应。 这项工作带来了有希望的治疗方法 用于病毒性淋巴瘤。 我继续研究其机制 这些药物在临床和实验室中的活性。 我们发现 抗病毒药物激活不同的细胞凋亡途径 叠氮胸苷和干扰素α在疱疹病毒淋巴瘤中的应用。 我们现在 研究决定敏感性的细胞和病毒因素或 阻力。 我感兴趣的另一个领域是培训以下领域的医生 病毒肿瘤学。 我的培训补助金让我能够吸引聪明的年轻人 该领域的医学博士和医学博士/博士。 每个同学都在研究一个 病毒肿瘤学的特定领域。 由于迈阿密是通往加勒比海的门户 和南美洲,我计划与这些受灾严重的地区发展合作 艾滋病和艾滋病相关癌症。 我还将利用培训计划 对病毒肿瘤学感兴趣的非洲医生。 我们已经建立了 承担这些任务的基础设施。 职业环境 发展非常好。 我的上级同意免除我的所有职责 与研究、指导和职业发展无关。 也许没有其他 医疗中心可以提供如此多样化的临床人群。 我受到支持 由临床和基础同行评审基金和癌症中心作为一项计划 领导者。 我还与我们的顶尖科学家开展了合作 进一步加强我的计划。 我的近期职业目标是确定 抗病毒介导的艾滋病淋巴瘤细胞凋亡机制并开发 我们病毒肿瘤学项目的临床和教育部分。 我的长 学期目标是发展我们的病毒肿瘤学项目,使我们得到认可 卓越的临床护理和研究,并将我们的研究扩展到拉丁语 美洲和非洲。 我作为导师的角色仍在继续。
英文摘要
DESCRIPTION (provided by applicant): I have reached a point in my career that requires singular dedication to my area of interest, viral oncology. Since my fellowship, I have been interested in lymphomas associated with viruses. There are many patients with these diseases at our medical center. HIV related lymphomas are common and Miami is an endemic area for HTLV-I therefore, Adult T Cell Leukemia is frequently seen. We have one of the largest organ transplant programs and there are many cases of post transplant lymphoproliferative disease. My emphasis has been on experimental therapeutics, specifically how certain viral lymphomas undergo apoptosis in response to antiviral agents. This work has resulted in promising treatments for viral lymphomas. I have continued to investigate the mechanisms of activity of these agents in the clinic and in the laboratory. We have found that distinct apoptotic pathways are activated by the antiviral agents Azidothymidine and Interferon alpha in herpes-virus Lymphomas. We are now investigating the cellular and viral factors which dictate sensitivity or resistance. My other area of interest is training physicians in the area of viral oncology. My training grant has allowed me to attract bright young M.D.'s and M.D./Ph.D.'s to this field. Each of the fellows is studying a specific area of viral oncology. Since Miami is the gateway to the Caribbean and South America, I plan to develop collaborations with these areas hard hit by AIDS and AIDS related cancers. I will also utilize a training program for African physicians interested in viral oncology. We have established infrastructures to undertake these tasks. The environment for career development is excellent. My superiors have agreed to free me of all duties unrelated to research, mentorship, and career development. Perhaps no other medical center could offer such a diverse clinical population. I am supported by clinical and basic peer reviewed funds and the cancer center as a program leader. I have also developed collaborations with our top scientists to further strengthen my program. My immediate career goal is to determine the mechanisms to antiviral mediated apoptosis in AIDS Lymphomas and develop the clinical and educational components of our viral oncology program. My long term goal is to develop our viral oncology program to where we are recognized for clinical care and research excellence and extend our studies to Latin America and Africa. My role as mentor is ongoing.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting of EBV Latency in Burkitt's Lymphoma
University of Miami
Targeted Therapy for Burkitt Lymphoma in Resource Poor Settings
Targeting of EBV Latency in Burkitt's Lymphoma
海外基金